Previous 10 | Next 10 |
2024-03-27 17:35:53 ET More on Achieve Life Sciences Achieve Life Sciences stock falls 11% amid FDA update, securities sale Seeking Alpha’s Quant Rating on Achieve Life Sciences Historical earnings data for Achieve Life Sciences Financial information f...
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced tha...
SEATTLE and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it ...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Smal...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7 th . This event is sponsored by Zacks Small-Cap Research. Individual investors, inst...
SEATTLE and VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that...
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds to conduct clinical development of cytisinicline through New Drug Application submission expected in 1H 2025, including the ORCA-O...
2024-02-16 09:10:00 ET February 16, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech sector. The newest biotech companies are involved in treatment of heart disease, ...
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14 th are now available for online viewing....
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and excellent compliance to study treatment Achieve expects to conduct an End-of...
LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 30 - May 2, 2024, where 96 MicroCap public and private companies will be presenting at the Paris Hotel & Casino in Las Vegas, NV. Event website: https://planetmi...
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutic...